1. Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience 
Mary A. Slatter, Kanchan Rao, Intan Juliana Abd Hamid, Zohreh Nademi, Robert Chiesa, Reem Elfeky, Mark S. Pearce, Persis Amrolia, Austen Worth, Terence Flood, Mario Abinun, Sophie Hambleton, Waseem Qasim, Hubert B. Gaspar, Andrew J. Cant, Andrew R. Gennery, Paul Veys 
Biology of Blood and Marrow Transplantation 
Volume 24, Issue 3, Pages (March 2018)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
OS.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Event-free survival. An event was death or additional procedure.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
T and myeloid cell chimerism according to stem cell source. All patients who survived longer than 1 year post-HSCT were included. Four patients without split cell lineage chimerism data were excluded.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
OS by diagnosis. Survival at 2 years post-HSCT: SCID, 94.6% (95% CI, 80.2% to 98.6%); WAS, 100%; CGD, 93.7% (95% CI, 63.2% to 99.1%); HLH, 62.5% (95% CI, 34.8% to 81.0%). P = .0001, log-rank test.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions